Doctor profile · Federal record
Dr. MEZGEBE BERHE, MD
Infectious Disease Physician (CMS: INFECTIOUS DISEASE) · Specialist · DALLAS, TX
- NPI 1831155787
- Accepts Medicare
- MIPS 75.0 / 100 · 2023
- 33 yrs in practice
- Male
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
3409 WORTH ST, 710
DALLAS, TX 752462029
(214) 823-2533
fax (214) 824-8679
Credentials & registration
- NPI registered
- April 2006 — 20 yrs on file
- Profile last updated
- October 12, 2023
- Year of graduation
- 1993 — 33 yrs since
- Specialty taxonomy
- 207RI0200X — NUCC code
- State license (1)
- Texas #M1510
- Medicaid
- TX #177738501
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1831155787. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
111,163
Distinct HCPCS
10
Medicare allowed
$1,780,489
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
J0485 |
Injection, belatacept, 1 mg | 62,980 | 13 | $4 | |
J0897 |
Injection, denosumab, 1 mg | 35,100 | 361 | $23 | |
J1561 |
Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 8,380 | 11 | $48 | |
96372 |
Injection of drug or substance under skin or into muscle | 795 | 384 | $14 | |
99232 |
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 774 | 280 | $78 | |
96365 |
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 608 | 134 | $65 | |
99233 |
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 565 | 207 | $117 | |
99214 |
Established patient office or other outpatient visit, 30-39 minutes | 498 | 172 | $104 | |
J3489 |
Injection, zoledronic acid, 1 mg | 345 | 69 | $9 | |
96366 |
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 224 | 14 | $21 |
In context: peer comparison
Among 36 peers in this city , average services per provider: 1,026. This provider delivers 108× the peer median.Open Payments
Industry payments received
All-time total
$3,051
Transactions
87
Manufacturers
10
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| ViiV Healthcare Company | 38 | $1,221.42 | |
| Gilead Sciences, Inc. | 14 | $956.24 | |
| Insmed, Inc. | 9 | $230.93 | |
| Shionogi Inc | 11 | $187.47 | |
| Merck Sharp & Dohme LLC | 4 | $161.57 | |
| ABBVIE INC. | 4 | $109.35 | |
| HOSPIRA, INC. | 3 | $52.94 | |
| Theratechnologies Inc. | 1 | $52.23 | |
| EMD Serono, Inc. | 2 | $48.75 | |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29.84 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
1,216
Patients
189
Total drug cost
$1,725,859
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Daptomycin | Generic | 220 | 40 | $256,070 |
| Ertapenem (Ertapenem Sodium) | Brand | 146 | 33 | $83,506 |
| Biktarvy (Bictegrav/Emtricit/Tenofov Ala) | Brand | 140 | 16 | $554,084 |
| Meropenem | Generic | 107 | 20 | $34,464 |
| Vancomycin Hcl | Generic | 97 | 17 | $16,201 |
| Ceftriaxone (Ceftriaxone Sodium) | Brand | 75 | 20 | $12,651 |
| Triumeq (Abacavir/Dolutegravir/Lamivudi) | Brand | 69 | 0 | $261,696 |
| Cefepime Hcl | Generic | 67 | 14 | $22,905 |
| Sulfamethoxazole-Trimethoprim (Sulfamethoxazole/Trimethoprim) | Brand | 59 | 18 | $929 |
| Tivicay (Dolutegravir Sodium) | Brand | 51 | 0 | $149,529 |